Treatment of osteoarthritis with a once-daily dosing regimen of celecoxib: A randomized, controlled trial

Journal of Clinical Rheumatology

Volumn 6, Issue 2, 2000, Pages 65-74

  Williams, Gary W ^a   Ettlinger, Robert E ^b   Ruderman, Eric M ^c   Hubbard, Richard C ^d   Lonien, Mary E ^d   Yu, Shawn S ^d   Zhao, William ^d   Geis, G Steven ^d  

^a SCRIPPS CLINIC   (United States)

^b Cedar Medical Center   (United States)

^c RUSH UNIVERSITY MEDICAL CENTER   (United States)

^d PFIZER INC   (United States)

Author keywords

Celecoxib; COX 2 specific inhibitor; Dose regimen; Osteoarthritis

Indexed keywords

CELECOXIB; NAPROXEN;

ADULT; AGED; ARTICLE; CATALYSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; ENZYME ACTIVITY; FEMALE; GASTROINTESTINAL MUCOSA; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OSTEOARTHRITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE ACTIVATION; TREATMENT FAILURE;

EID: 0034090905     PISSN: 10761608     EISSN: None     Source Type: Journal    
DOI: 10.1097/00124743-200004000-00002     Document Type: Article

References (27)

1. Abramson SR, Weissman G. The mechanisms of action of nonsteroidal anti-inflammatory drugs. Arthritis Rheum 1989;32:1-9.
2. Smith WL, DeWitt DL. Prostaglandin endoperoxide H synthases-1 and -2. Adv Immunol 1996;62:167-215.
3. Kargman S, Charleson S, Cartwright M, Frank J, Riendeau D, Mancini J. Characterization of prostaglandin G/H synthase 1 and 2 in rat, monkey, and human gastrointestinal tracts. Gastroenterology 1996;111:445-54.
4. Schafer AI. Effects of nonsteroidal anti-inflammatory therapy on platelets. Am J Med 1999; 106 Suppl 5B:25S-36S.
5. Masferrer JL, Zweifel BS, Manning PT, Hauser SD, Leahy KM, Smith WG. Selective inhibition of inducible cyclooxygenase 2 in vivo is antiinflammatory and nonulcerogenic. Proc Natl Acad Sci USA 1994;91:3228-32.
6. Seibert K, Zhang Y, Leahy K, Hauser S, Masferrer J, Perkins W. Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain. Proc Natl Acad Sci USA 1994;91:12013-7.
7. Crofford LJ, Wilder RL, Ristimäki AP, Sano H, Remmers EF, Epps HR. Cyclooxygenase-1 and -2 expression in rheumatoid synovial tissues: effects of interleukin-1, phorbol ester, and corticosteroids. J Clin Invest 1994;93:1095-101.
8. Singh G, Ramey DR. NSAID-induced gastrointestinal complications: the ARAMIS perspective-1997. J Rheumatol 1998;25 Suppl 51: 8-16.
9. Silverstein FE, Graham DY, Senior JR, Davies HW, Struthers BJ, Bittman RM, et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995; 123:241-9.
10. Cheatum DE, Arvanitakis C, Gumpel M, Stead H, Geis GS. An endoscopic study of gastroduodenal lesions induced by nonsteroidal anti-inflammatory drugs. Clin Ther 1999;21: 992-1003.
11. Simon LS, Lanza FL, Lipsky PE, Hubbard RC, Talwalker S, Schwartz BD. Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor. Arthritis Rheum 1998;41:1591-1602.
12. Emery P, Zeidler H, Kvien TK, Guslandi M, Naudin R, Stead H. Randomised double-blind comparison of celecoxib versus diclofenac in long-term management of rheumatoid arthritis. Lancet 1999;354:2105-11.
13. Bensen WG, Fiechtner JJ, McMillen JI, Zhao WW, Yu SS, Woods EM. Treatment of osteoarthritis with celecoxib, a cyclooxygenase-2 inhibitor. Mayo Clin Proc 1999;74:1095-1105.
14. Celebrex [package insert]. Skokie, IL: G.D. Searle & Co. and Groton, CN: Pfizer; December 31, 1998.
15. Gierse JK, Koboldt CM, Walker MC, Seibert K, Isakson PC. Kinetic basis for selective inhibition of cyclo-oxygenase. Biochem J 1999;339;607-14.
16. Altman R, Asch E, Bloch G, Bole G, Borenstein D, Brandt K. Development of criteria for the classification and reporting of osteoarthritis: classification of osteoarthritis of the knee. Arthritis Rheum 1986;29:1039-49.
17. Klippel JH, editors. Primer on the rheumatic diseases. 11th ed, Atlanta, GA: Arthritis Foundation; 1997.
18. Steinbrocker O, Traeger CH, Batterman RC. Therapeutic criteria in rheumatoid arthritis. JAMA 1949;140:659-62.
19. American Rheumatism Association Glossary Committee. Dictionary of the rheumatic diseases. Vol 1. Signs and symptoms. New York: Contact Associates International Ltd; 1988.
20. Lequesne MG, Mery C, Samson M, Gerard P. Indexes of severity of osteoarthritis of the hip and knee: validation - value in comparison with other assessment tests. Scand J Rheumatol 1987; Suppl 65:85-9.
21. Bellamy N. WOMAC Osteoarthritis index: a user's guide. Ontario: The Western Ontario and McMaster Universities; 1995.
22. Sclar DA, Tartaglione TA, Fine MJ. Overview of issues related to medical compliance with implications for the outpatient management of infectious diseases. Infect Agents Dis 1994;3:266-73.
23. Lawrence RC, Helmick CG, Arnett FC, Dayo RA, Felson DT, Giannini EH. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum 1998;41:778-99.
24. Simon LS, Weaver AL, Graham DY, Kivitz AJ, Lipsky PE, Hubbard RC. The anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized, controlled trial. JAMA 1999; 282:1921-8.
25. Bocanegra TS, Weaver AL, Tindall EA, Sikes DH, Ball JA, Wallemark CB. Diclofenac/misoprostol compared with diclofenac in the treatment of osteoarthritis of the knee or hip: a randomized, placebo controlled trial. J Rheumatol 1998;25:1602-11.
26. Poiley JE. Nabumetone versus naproxen in the treatment of osteoarthritis: a six-month trial. Am J Med 1987;83 Suppl 4B:82-5.
27. Melo Gomes JA, Roth SH, Zeeh J, Bruyn GAW, Woods EM, Geis GS. Double-blind comparison of efficacy and gastroduodenal safety of diclofenac/misoprostol, piroxicam, and naproxen in the treatment of osteoarthritis. Ann Rheum Dis 1993;52:881-5.